Inhibrx (INBX) Competitors $14.54 +0.21 (+1.47%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INBX vs. NTLA, CRON, REPL, IMTX, GYRE, DAWN, VIR, AVXL, ABUS, and EOLSShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Intellia Therapeutics (NTLA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Its Competitors Intellia Therapeutics Cronos Group Replimune Group Immatics Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus Intellia Therapeutics (NASDAQ:NTLA) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Is NTLA or INBX more profitable? Intellia Therapeutics' return on equity of -49.34% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Inhibrx N/A -113.74%-80.56% Do analysts prefer NTLA or INBX? Intellia Therapeutics currently has a consensus price target of $34.95, suggesting a potential upside of 322.87%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.67Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings & valuation, NTLA or INBX? Inhibrx has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$45.57M18.79-$481.19M-$5.23-1.58Inhibrx$200K1,052.41-$154.96M$116.750.12 Does the MarketBeat Community favor NTLA or INBX? Intellia Therapeutics received 418 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 68.76% of users gave Intellia Therapeutics an outperform vote while only 57.41% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44968.76% Underperform Votes20431.24% InhibrxOutperform Votes3157.41% Underperform Votes2342.59% Do institutionals & insiders hold more shares of NTLA or INBX? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 17.1% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor NTLA or INBX? In the previous week, Intellia Therapeutics had 8 more articles in the media than Inhibrx. MarketBeat recorded 9 mentions for Intellia Therapeutics and 1 mentions for Inhibrx. Inhibrx's average media sentiment score of 1.87 beat Intellia Therapeutics' score of 0.81 indicating that Inhibrx is being referred to more favorably in the news media. Company Overall Sentiment Intellia Therapeutics Positive Inhibrx Very Positive SummaryIntellia Therapeutics beats Inhibrx on 11 of the 17 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.48M$3.10B$5.61B$8.54BDividend YieldN/A1.56%5.28%4.17%P/E Ratio0.1232.5927.1819.77Price / Sales1,052.41459.71411.66152.70Price / CashN/A168.6838.3234.64Price / BookN/A3.376.984.63Net Income-$154.96M-$72.35M$3.24B$248.14M7 Day Performance4.45%0.94%-0.29%-0.46%1 Month Performance28.90%18.06%8.48%4.16%1 Year Performance-12.36%-18.20%32.16%13.35% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx2.9161 of 5 stars$14.54+1.5%N/A-13.3%$210.48M$200K0.12166Positive NewsUpcoming EarningsGap DownNTLAIntellia Therapeutics4.6044 of 5 stars$7.16+4.2%$36.75+413.3%-67.7%$741.65M$45.57M-1.32600Analyst RevisionHigh Trading VolumeCRONCronos Group1.9169 of 5 stars$1.92-3.0%N/A-20.4%$739.98M$124.59M-14.77450Positive NewsREPLReplimune Group4.5081 of 5 stars$9.57+6.6%$19.75+106.4%+12.1%$737.72MN/A-3.12210Positive NewsHigh Trading VolumeIMTXImmatics2.6422 of 5 stars$6.01+11.5%$14.67+144.0%-53.2%$730.52M$144.15M-9.11260Analyst RevisionGap UpHigh Trading VolumeGYREGyre Therapeutics0.3225 of 5 stars$7.68-15.3%N/A-24.0%$720.06M$100.64M384.0040Short Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.6242 of 5 stars$7.01+9.9%$30.57+336.1%-48.5%$710.55M$161.92M-6.8160VIRVir Biotechnology3.0332 of 5 stars$5.07+2.6%$32.86+548.1%-50.2%$700.87M$14.30M-1.29580Positive NewsAVXLAnavex Life Sciences3.9156 of 5 stars$7.56+0.4%$44.00+482.0%+119.2%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.2577 of 5 stars$3.36flat$5.50+63.7%+10.2%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.0974 of 5 stars$9.97+8.5%$23.75+138.2%-11.7%$642.83M$275.46M-10.96170Positive NewsInsider TradeHigh Trading Volume Related Companies and Tools Related Companies Intellia Therapeutics Alternatives Cronos Group Alternatives Replimune Group Alternatives Immatics Alternatives Gyre Therapeutics Alternatives Day One Biopharmaceuticals Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Arbutus Biopharma Alternatives Evolus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INBX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INBX Stock Free INBX Stock Alerts